Plaque Psoriasis

FDA Expands Ustekinumab to Pediatric Plaque Psoriasis

July 31, 2020


The expansion makes history for the injection biologic.

Netakimab Rapidly Improves Axial Disease

June 05, 2020


The findings are based on data from a 24-week observation from an ongoing phase 3 PATERA study.

Biologics Do Not Increase Melanoma Risk in Patients With Inflammatory Disease

May 20, 2020


There is no significant association between biologic exposure and the development of melanoma in patients with IBD, rheumatoid arthritis, or psoriasis.

Top-Line Results Positive for New Plaque Psoriasis Treatment

May 08, 2020


Investigators found 30 mg of apremilast results in a significant reduction in plaque psoriasis patients.

Psoriasis Patients with Mental Illness Report Worse Clinical Interaction

May 06, 2020


An assessment of survey data show patients with severe depressive or psychological symptoms are more likely to be dissatisfied with their dermatologist.

How COVID-19 Affects Dermatology

May 05, 2020


A dermatologist discusses how to care for patients with psoriasis during the COVID-19 pandemic.

Ixekizumab Continues to Build Chronic Care Portfolio

April 15, 2020


The IL-17A-targeting biologic has now been indicated for pediatric plaque psoriasis—marking its fourth indication for patients with chronic diseases.

Risankizumab Benefits Chronic Plaque Psoriasis at 2 Years

April 08, 2020


New phase 3 IMMhance findings show durable, sustained effect of the IL-23 inhibitor on a 12-week dose regimen.

AAD House Call: ARQ-151 for Chronic Plaque Psoriasis

March 21, 2020


Lisa Stein Gold, MD, of Henry Ford Hospital discusses promising phase 2 data for a new PDE4 inhibitor.

Psoriasis Increases Cancer Risk

February 24, 2020


Patients with psoriatic arthritis are not at an increased risk of cancer, however.